Format

Send to

Choose Destination
Front Pharmacol. 2018 Apr 10;9:325. doi: 10.3389/fphar.2018.00325. eCollection 2018.

Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Author information

1
Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
2
Department of Neurology and Neuroscience, Medical School, Federal University of São Paulo, São Paulo, Brazil.

Abstract

Since proving adenosine triphosphate (ATP) functions as a neurotransmitter in neuron/glia interactions, the purinergic system has been more intensely studied within the scope of the central nervous system. In neurological disorders with associated motor symptoms, including Parkinson's disease (PD), motor neuron diseases (MND), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington's Disease (HD), restless leg syndrome (RLS), and ataxias, alterations in purinergic receptor expression and activity have been noted, indicating a potential role for this system in disease etiology and progression. In neurodegenerative conditions, neural cell death provokes extensive ATP release and alters calcium signaling through purinergic receptor modulation. Consequently, neuroinflammatory responses, excitotoxicity and apoptosis are directly or indirectly induced. This review analyzes currently available data, which suggests involvement of the purinergic system in neuro-associated motor dysfunctions and underlying mechanisms. Possible targets for pharmacological interventions are also discussed.

KEYWORDS:

Huntington's disease; Parkinson's disease; amyotrophic lateral sclerosis (ALS); ataxia; multiple sclerosis; neurodegeneration; purinergic receptors; restless leg syndrome

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center